BIOLOGICAL PREPARATIONS COMPRISING EXTRACELLULAR VESICLES

Brand Owner (click to sort) Address Description
CODIAK Codiak Biosciences, Inc. 35 Cambridge Park Drive, Suite 500 Cambridge MA 02140 Biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications, namely, biological preparations for the treatment of metabolic and fibrotic disorders, immune diseases, cancer, and neurological disorders; all of the foregoing excluding pharmaceutical drugs and medicines to treat ophthalmic diseases and diagnostic reagents for medical use;Biopharmaceutical research and development services related to extracellular vesicles known as exosomes, the foregoing excluding research and development related to ophthalmology or diagnostic reagents;
CODIAK BIOSCIENCES Codiak Biosciences, Inc. 35 Cambridge Park Drive, Suite 500 Cambridge MA 02140 Biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications, namely, biological preparations for the treatment of metabolic and fibrotic disorders, immune diseases, cancer, and neurological disorders; all of the foregoing excluding pharmaceutical drugs and medicines to treat ophthalmic diseases and diagnostic reagents for medical use;BIOSCIENCES;Biopharmaceutical research and development services related to extracellular vesicles known as exosomes, the foregoing excluding research and development related to ophthalmology or diagnostic reagents;
ENGEX - AAV Codiak Biosciences, Inc. 35 Cambridge Park Drive, Suite 500 Cambridge MA 02140 Biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurological disorders, vaccination, and rare diseases;AAV;Biopharmaceutical research and development services; pharmaceutical research and development services;
ENGEX - ASO Codiak Biosciences, Inc. 35 Cambridge Park Drive, Suite 500 Cambridge MA 02140 Biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurological disorders, vaccination, and rare diseases;Biological preparations comprising extracellular vesicles known as exosomes for use in the manufacture of pharmaceuticals in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurological disorders, vaccination, and rare diseases;ASO;Biopharmaceutical research and development services; pharmaceutical research and development services;
ENGEX - PMO Codiak Biosciences, Inc. 35 Cambridge Park Drive, Suite 500 Cambridge MA 02140 Biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurological disorders, vaccination, and rare diseases;PMO;Biopharmaceutical research and development services; pharmaceutical research and development services;
ENGEX - SIRNA Codiak Biosciences, Inc. 35 Cambridge Park Drive, Suite 500 Cambridge MA 02140 Biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurological disorders, vaccination, and rare diseases;SIRNA;
EXOASO Codiak Biosciences, Inc. 35 Cambridge Park Drive, Suite 500 Cambridge MA 02140 Biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications for the treatment of neurological and physiological disorders, namely, cancer, immune-based diseases, metabolic and fibrotic disorders, infectious diseases, and rare diseases; biological preparations comprising extracellular vesicles known as exosomes for use in the manufacture of pharmaceuticals in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neourological disorders, vaccination, and rare diseases;Biopharmaceutical research and development services; pharmaceutical research and development services;
EXOEDIT Codiak Biosciences, Inc. 35 Cambridge Park Drive, Suite 500 Cambridge MA 02140 Biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurological disorders, vaccination, and rare diseases;
EXOPMO Codiak Biosciences, Inc. 35 Cambridge Park Drive, Suite 500 Cambridge MA 02140 Biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurological disorders, vaccination, and rare diseases;
EXOSTING Codiak Biosciences, Inc. 35 Cambridge Park Drive, Suite 500 Cambridge MA 02140 Biological preparations comprising extracellular vesicles known as exosomes for therapeutic applications for the treatment of neurological and physiological disorders, namely, cancer, immune-based diseases, metabolic and fibrotic disorders, infectious diseases, and rare diseases; biological preparations comprising extracellular vesicles known as exosomes for use in the manufacture of pharmaceuticals in the areas of oncology, immune-based diseases, metabolic and fibrotic disorders, neurological disorders, vaccination, and rare diseases;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.